Form 4: RAPT Therapeutics Director, Mary Ann Gray, Acquires Stock Options in Lieu of Cash Compensation

Director Mary Ann Gray acquired stock options for 61,202 shares of RAPT Therapeutics at an exercise price of $1.22, vesting quarterly throughout 2025, in lieu of $65,000 in cash retainers.

Summary

• Mary Ann Gray, a director at RAPT Therapeutics, acquired stock options on March 31, 2025.
• The options are for 61,202 shares of common stock with an exercise price of $1.22 per share.
• The options vest in four equal quarterly installments throughout 2025, starting on March 31, 2025, contingent upon continued service as a director.
• These options were granted in lieu of $65,000 in annual cash retainers for board and committee service, according to the Issuer's Amended and Restated Non-Employee Director Compensation Policy.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects standard compensation practice, aligning director interests with shareholders without indicating any specific financial distress or exceptional performance.

Positives

• The acquisition of stock options by a director aligns their interests with those of the shareholders.
• Replacing cash compensation with stock options can conserve company cash.

Industry Context

Granting stock options to directors is a common practice to align their interests with shareholders and conserve cash, particularly for companies in the biotechnology sector.

Comparison to Industry Standards

• Many biotech companies use equity compensation for board members.
• The specific amount and vesting schedule would need to be compared to peer companies of similar size and stage of development to assess if it is in line with industry standards.
• Companies like Amgen, Gilead, and Biogen also use stock options as part of their director compensation packages.

Stakeholder Impact

• Shareholders may view this as a positive move, aligning director interests with company performance.
• Employees may see this as a sign of the company's commitment to conserving cash.

Key Dates

Keywords

RAPT Therapeutics, stock options, director compensation, Form 4, insider trading, Mary Ann Gray, equity compensation